These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 18520229)

  • 1. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
    Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM
    Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).
    Martín J; Poveda A; Llombart-Bosch A; Ramos R; López-Guerrero JA; García del Muro J; Maurel J; Calabuig S; Gutierrez A; González de Sande JL; Martínez J; De Juan A; Laínez N; Losa F; Alija V; Escudero P; Casado A; García P; Blanco R; Buesa JM;
    J Clin Oncol; 2005 Sep; 23(25):6190-8. PubMed ID: 16135486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
    Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
    Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M; Sobin LH; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
    Andersson J; Bümming P; Meis-Kindblom JM; Sihto H; Nupponen N; Joensuu H; Odén A; Gustavsson B; Kindblom LG; Nilsson B
    Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors.
    Tzen CY; Wang MN; Mau BL
    Eur J Surg Oncol; 2008 May; 34(5):563-8. PubMed ID: 17532173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
    Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
    J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases.
    Yamamoto H; Kojima A; Nagata S; Tomita Y; Takahashi S; Oda Y
    Am J Surg Pathol; 2011 Sep; 35(9):1287-95. PubMed ID: 21836495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
    Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
    J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors.
    Braggio E; Braggio Dde A; Small IA; Lopes LF; Valadão M; Gouveia ME; Moreira Ados S; Linhares E; Romano S; Bacchi CE; Renault IZ; Guimarães DP; Ferreira CG
    Anticancer Res; 2010 Jun; 30(6):2407-14. PubMed ID: 20651400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Status and clinical analysis of c-kit and PDGFRA mutations in the gastrointestinal stromal tumors].
    Du CY; Shi YQ; Zhou Y; Fu H; Zhao GF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):371-5. PubMed ID: 18636362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S; Chen LR; Wang HJ; Chen SZ
    Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours.
    Ryu MH; Kang YK; Jang SJ; Kim TW; Lee H; Kim JS; Park YH; Lee SS; Ryoo BY; Chang HM; Lee JL; Yook JH; Kim BS; Lee JS
    Histopathology; 2007 Sep; 51(3):379-89. PubMed ID: 17727479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and prognostic factors analysis in surgically resected gastrointestinal stromal tumor patients.
    Song Z; Wang JL; Pan YL; Tao DY; Gan MF; Huang KE
    Hepatogastroenterology; 2009; 56(89):149-53. PubMed ID: 19453047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era.
    Iesalnieks I; Rümmele P; Dietmaier W; Jantsch T; Zülke C; Schlitt HJ; Hofstädter F; Anthuber M
    Am J Clin Pathol; 2005 Nov; 124(5):740-8. PubMed ID: 16203282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.
    Penzel R; Aulmann S; Moock M; Schwarzbach M; Rieker RJ; Mechtersheimer G
    J Clin Pathol; 2005 Jun; 58(6):634-9. PubMed ID: 15917417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.
    Haller F; Gunawan B; von Heydebreck A; Schwager S; Schulten HJ; Wolf-Salgó J; Langer C; Ramadori G; Sültmann H; Füzesi L
    Clin Cancer Res; 2005 Sep; 11(18):6589-97. PubMed ID: 16166437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic targets in gastrointestinal stromal tumors].
    Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
    Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.